Kite Pharma, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Kite Pharma, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 16 February 2016 (Cession). Among the most active insiders: Sproule Rizwana F. All data is accessible without an account.
Analyst consensus: bullish or bearish? Analysts rate Kite Pharma, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 February 2016
All Executives46 Thresholds0 Prospectus0 Other0
Declarations 46 total
▼ Chief Scientific Officer · Executives · 12 Feb 2016
18,750 shares Common Stock SEC:0001209191-16-098979:1
◇ Chief Scientific Officer · Executives · 12 Feb 2016
18,750 shares Common Stock SEC:0001209191-16-098979:0
◇ COO and CFO · Executives · 2 Feb 2016
1,900 shares Common Stock SEC:0001209191-16-095879:0
▼ COO and CFO · Executives · 2 Feb 2016
1,900 shares Common Stock SEC:0001209191-16-095879:1
◇ VP, Product Sciences · Executives · 1 Feb 2016
9,000 shares Common Stock SEC:0001209191-16-095525:0
▼ VP, Product Sciences · Executives · 1 Feb 2016
2,499 shares Common Stock SEC:0001209191-16-095525:1
▼ VP, Product Sciences · Executives · 1 Feb 2016
4,938 shares Common Stock SEC:0001209191-16-095525:2
▼ VP, Product Sciences · Executives · 1 Feb 2016
1,410 shares Common Stock SEC:0001209191-16-095525:3
▼ VP, Product Sciences · Executives · 1 Feb 2016
153 shares Common Stock SEC:0001209191-16-095525:4
◇ COO and CFO · Executives · 27 Jan 2016
8,100 shares Common Stock SEC:0001209191-16-094259:0
▼ COO and CFO · Executives · 27 Jan 2016
2,500 shares Common Stock SEC:0001209191-16-094259:1
▼ COO and CFO · Executives · 27 Jan 2016
2,700 shares Common Stock SEC:0001209191-16-094259:2
▼ COO and CFO · Executives · 27 Jan 2016
2,800 shares Common Stock SEC:0001209191-16-094259:3
▼ COO and CFO · Executives · 27 Jan 2016
100 shares Common Stock SEC:0001209191-16-094259:4
◇ Chief Scientific Officer · Executives · 15 Jan 2016
5,500 shares Common Stock SEC:0001209191-16-092245:0
◇ Chief Scientific Officer · Executives · 15 Jan 2016
645 shares Common Stock SEC:0001209191-16-092245:1
▼ Chief Scientific Officer · Executives · 15 Jan 2016
264 shares Common Stock SEC:0001209191-16-092245:2
▼ Chief Scientific Officer · Executives · 15 Jan 2016
700 shares Common Stock SEC:0001209191-16-092245:3
▼ Chief Scientific Officer · Executives · 15 Jan 2016
3,527 shares Common Stock SEC:0001209191-16-092245:4
▼ Chief Scientific Officer · Executives · 15 Jan 2016
1,054 shares Common Stock SEC:0001209191-16-092245:5
▼ VP Regulatory Affairs · Executives · 15 Jan 2016
645 shares Common Stock SEC:0001209191-16-092246:2
▼ VP Regulatory Affairs · Executives · 15 Jan 2016
3,166 shares Common Stock SEC:0001209191-16-092246:3
▼ VP Regulatory Affairs · Executives · 15 Jan 2016
1,918 shares Common Stock SEC:0001209191-16-092246:4
▼ VP Regulatory Affairs · Executives · 15 Jan 2016
800 shares Common Stock SEC:0001209191-16-092246:5
◇ VP Regulatory Affairs · Executives · 19 Jan 2016
2,767 shares Common Stock SEC:0001209191-16-092246:6
25 of 46 declarations
Load more (21 remaining) 关于 Kite Pharma, Inc. Kite Pharma, Inc. 是一家生物制药公司,专注于开发用于癌症治疗的细胞疗法。该公司在纳斯达克上市,股票代码为 KITE。